AA型淀粉样变揭示甲羟戊酸激酶缺乏症:20例报告及文献综述
本文通过系统文献综述和2例新发法国病例,描述了20例甲羟戊酸激酶缺乏症(MKD)患者中出现的炎症性A淀粉样变(AA)。AA淀粉样变在MKD中似乎罕见,肾功能损害始终是其首发症状,最常见基因型为V377I/I268T,部分生物制剂治疗部分有效,但仍有患者死亡或需肾移植。
要点
- MKD患者出现肾功能损害时应警惕AA淀粉样变,其为首发症状。
- V377I/I268T为最常见基因型,所有携带MVK致病突变者疾病均在4岁内起病。
- 秋水仙碱无效,抗IL-1、抗TNF或抗IL-6生物制剂部分有效。
核心结论
- 炎症性A淀粉样变是MKD的罕见并发症,可导致死亡或需肾移植,早期诊断和细胞因子阻断生物治疗是必要的。
研究设计与样本
- 系统文献综述及2例新发法国病例报告,共纳入20例MKD合并AA淀粉样变患者。
- MVK基因研究在20例中的18例可用,所有检测个体均确认两个致病突变。
主要发现
- AA淀粉样变发生于20例MKD患者,肾功能损害始终是AA的首发症状。
- 肾病综合征(n=15)、终末期肾衰竭(n=5)或两者兼有(n=8)提示肾脏淀粉样变。
- 最年轻肾淀粉样变患者为欧洲4岁女孩,此前被误诊为PFAPA综合征。
- 5例患者死于AA淀粉样变,其中2例使用了生物制剂;9例进行了肾移植。
- 秋水仙碱对所有患者均无效;抗IL-1阿那白滞素(n=8)、抗TNF依那西普(n=7)和抗IL-6托珠单抗(n=5)治疗部分有效。
关键数值与推荐
- 最常见基因型为V377I/I268T(n=9/18)。
- 所有携带MVK致病突变的患者疾病起病均在生命最初4年内。
- 若估计全球MKD患病率为300例,AA在MKD中似乎罕见(约6%)。
临床怎么用
- 对MKD患者应监测肾功能,出现蛋白尿或肾功能损害时需排查AA淀粉样变。
- 确诊AA淀粉样变后,应尽早使用抗IL-1、抗TNF或抗IL-6生物制剂以预防终末期肾衰竭。
- 秋水仙碱无效,不应作为AA淀粉样变的治疗选择。
局限性
- 由于MKD确切患病率未知,无法准确估计AA淀粉样变的患病率。
- 本文为回顾性综述和病例报告,治疗疗效证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mevalonate kinase deficiency (MKD) is a rare autosomal recessive autoinflammatory disease that can lead to an inflammatory A amyloidosis (AA). METHODS: To study the occurrence of AA in MKD patients we performed a systemic review of the literature and described two novel patients. RESULTS: Amyloidosis occurred in 20 MKD patients, renal impairment being always the revealing symptom of AA. Although an accurate prevalence estimation is not possible since exact MKD prevalence is unknown, AA seems rare in MKD (about 6% if we estimate MKD prevalence at 300 patients worldwide). MVK gene study, available in 18 out of the 20 patients, confirmed two pathogenic mutations in all tested individuals. The most frequent genotype was V377I/I268T (n = 9/18). Retrospective search of clinical signs of MKD established, in all patients carrying MVK pathogenic mutations, a disease onset within the first four years of life. Nephrotic syndrome (n = 15), end-stage renal failure (n = 5) or both (n = 8) pointed out kidney amyloidosis. The youngest patient with renal amyloidosis was a European four-year-old girl previously misdiagnosed with PFAPA syndrome. Five patients died of AA amyloidosis despite the use of a biotherapy for two of them; kidney transplant was performed in nine individuals. Colchicine was not effective in any patient. Anti-interleukin-1 anakinra (n = 8), anti TNF etanercept (n = 7) and anti-interleukin 6 tocilizumab (n = 5) treatments were partially effective. CONCLUSION: Inflammatory A amyloidosis, a rare complication of MKD, can cause death or necessitate kidney transplantation. Early diagnosis and cytokine blocking biotherapy using anti-IL1, anti-TNF or anti-IL6 agents are required to prevent terminal renal failure.
引用
- Rodrigues F, Philit JB, Giurgea I, et al. AA amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature. Semin Arthritis Rheum. 2020. PMID: 32252977. doi:10.1016/j.semarthrit.2020.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。